This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
by Zacks Equity Research
Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.
ARCTNegative Net Change STRONegative Net Change FULCNegative Net Change BVSPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Klaviyo, Inc. (KVYO) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
KVYONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Genpact (G) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
GPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BeiGene, Ltd. (BGNE) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
BGNEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
by Zacks Equity Research
Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.
REGNNegative Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bayer (BAYRY) Starts Mid-Stage Study on Chronic Kidney Disease Drug
by Zacks Equity Research
Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.
LLYPositive Net Change BAYRYPositive Net Change EXELNegative Net Change
biotechnology medical pharmaceuticals
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study
by Zacks Equity Research
Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.
ARCTNegative Net Change GLPGNegative Net Change FULCNegative Net Change BVSPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Energy Fuels (UUUU) Enters Medical Isotope Market: Buy the Stock?
by Madhurima Das
Energy Fuels (UUUU) buys RadTran to leverage know-how to produce medical isotopes used in cancer treatments. Let us find out whether this can boost the stock.
CCJNegative Net Change UUUUNegative Net Change UECNegative Net Change
basic-materials biotechnology biotechs
Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review
by Zacks Equity Research
Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.
AZNPositive Net Change BMYPositive Net Change ILMNPositive Net Change ARCTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug
by Zacks Equity Research
Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug.
RDYNegative Net Change ILMNPositive Net Change ARCTNegative Net Change HLNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
by Zacks Equity Research
Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.
ILMNPositive Net Change NBIXNegative Net Change ARCTNegative Net Change XENENegative Net Change
biotechnology biotechs medical pharmaceuticals
VICI Properties Inc. (VICI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
VICIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
F5 Networks (FFIV)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
FFIVNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News
by Ekta Bagri
Bigwigs Regeneron (REGN) and Gilead Sciences (GILD) are in the spotlight following regulatory updates and drug approval, respectively.
REGNNegative Net Change GILDNegative Net Change INCYPositive Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug
by Zacks Equity Research
Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.
REGNNegative Net Change SNYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated
by Zacks Equity Research
Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.
BMYPositive Net Change BMRNNegative Net Change KRYSNegative Net Change
biotechnology biotechs immuno-therapy pharmaceuticals
Kymera (KYMR) to Raise $225 Million Through Offering of Shares
by Zacks Equity Research
Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering.
SNYPositive Net Change BMYPositive Net Change KRYSNegative Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed
by Andrew Rocco
Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.
NVOPositive Net Change LLYPositive Net Change SBUXNegative Net Change MCDPositive Net Change SHAKNegative Net Change
biotechnology biotechs
AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use
by Zacks Equity Research
AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.
ILMNPositive Net Change ARCTNegative Net Change ABBVNegative Net Change GMABPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Zacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions
by Zacks Equity Research
Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions have been highlighted in this Investment Ideas article.
APDNNegative Net Change EBSPositive Net Change GOVXNegative Net Change VRAXNegative Net Change
biotechnology
ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?
by Ekta Bagri
The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.
GRFSNegative Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
by Andrew Rocco
Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.
APDNNegative Net Change TNXPNegative Net Change EBSPositive Net Change GOVXNegative Net Change VRAXNegative Net Change
biotechnology biotechs coronavirus vaccines
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
by Zacks Equity Research
AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.
ILMNPositive Net Change ARCTNegative Net Change ANTXPositive Net Change FULCNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Heritage Insurance (HRTG) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
HRTGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Allegion (ALLE)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ALLEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines